Not Yet RecruitingNot Applicable

Comparison of Efficacy and Safety Between Ciprofol and Remimazolam During Fiberoptic Bronchoscopy

190 participantsStarted 2024-12-01

Plain-language summary

Both ciprofol and remimazolam have been found to be potential alternatives to propofol (a commonly used anesthesia) during fiberoptic bronchoscopy, while the efficacy and safety between ciprofol and remimazolam have not been reported. This study aims to compare the efficacy and safety between ciprofol and remimazolam in patients undergoing fiberoptic bronchoscopy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. male or female patients with age ≥ 18 years old;
✓. scheduled to undergo bronchoscopy under laryngeal mask airway;
✓. with American Society of Anesthesiologists (ASA) physical status classes II to Ⅲ; and
✓. volunteering to participate in this study and signing an informed consent form.

Exclusion criteria

✕. with contraindications to deep sedation/general anesthesia or with a history of sedation/anesthesia accidents;
✕. allergic to eggs, bean products, or experimental drugs (ciprofol, sufentanil, or remimazolam);
✕. difficult airway;
✕. with bradycardia or other serious cardiovascular diseases;
✕. with severe damages or diseases in important organs such as the lungs, brain, liver, or kidneys;
✕. using sedatives or antidepressants for a long time;
✕. pregnant or lactating women; and (8) unable to communicate or cooperate.

What they're measuring

The success rate of fiberoptic bronchoscopy

Timeframe: 24 hours after fiberoptic bronchoscopy

Trial details

NCT IDNCT06531915

SponsorAnhui Provincial Hospital

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2024-12-30

View on ClinicalTrials.gov More Fiberoptic Bronchoscopy trials